Pfizer Raises 2026 Guidance After Strong Third-Quarter Results
Pfizer’s strong Q3 2026 results and raised full-year guidance provide a constructive signal on earnings momentum heading into year-end.
Waters’ MOBILion Acquisition Signals Continued Consolidation in Life-Sciences Tools
Waters’ planned MOBILion acquisition could broaden its analytical-instrumentation portfolio and reinforce its role in pharmaceutical and biotech resea…
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Bright Minds Biosciences Stock Plunges 52% After FDA Places Epilepsy Trial on Hold
Bright Minds Biosciences shares fell as much as 52% after the FDA placed its BMB-101 epilepsy trial on clinical hold.
Lupin Wins US FDA Approval for Amifampridine Tablets
Lupin’s November 2 FDA approval for amifampridine adds a potential rare-disease growth catalyst, though commercial impac…
Karyopharm Bankruptcy and Ayrmid Merger Put Pharma Restructuring in Focus
Karyopharm’s bankruptcy protection filing and planned merger with Ayrmid highlight the growing role of restructuring-dri…
Axsome’s Q3 Update Gives AXSM Investors a Read on CNS Commercial Execution
Axsome’s third-quarter update gives AXSM investors a results-day lens on CNS commercial execution, pipeline momentum and…
uniQure’s QURE Shares Enter the Spotlight After FDA Grants Huntington’s Gene-Therapy Priority Review
FDA acceptance and Priority Review for uniQure’s Huntington’s gene-therapy application create a potentially important ca…
Karyopharm Bankruptcy and Ayrmid Merger Put Shareholder Recovery in Focus
Karyopharm’s bankruptcy filing and planned Ayrmid merger highlight creditor priority and uncertainty over any recovery f…
Vanda Revenue Climbs 24%, but Cash Burn Raises Liquidity Questions for VNDA Investors
Vanda’s Q3 revenue rose 24%, but a $123.4 million liquidity decline and higher expected cash burn complicate the Nasdaq-…
AbbVie Raises Full-Year Outlook After Q3 Beat as Skyrizi Pipeline Expands
AbbVie beat Q3 2026 estimates and raised its full-year outlook while advancing Skyrizi combinations and reporting positi…
AstraZeneca ADR Jumps 7% After Q3 Beat as Tagrisso and Baxfendy Drive Momentum
AstraZeneca's Nasdaq-listed ADR rose 7% after a Q3 beat, with Tagrisso sales and respiratory pipeline progress supportin…